In this study, GNG4 was significantly hypermethylated and one of the top 10 significantly down-regulated genes in NAFLD HCC patients with cirrhosis, suggesting that GNG4 may be a potential clinical therapeutic target for NAFLD HCC patients with cirrhosis by inhibiting tumor metastasis. Here, GNG4 is linked to metabolic dysfunction-associated steatotic liver disease.